ARTICLE | Company News
Amarillo, Atrix deal
October 8, 2001 7:00 AM UTC
AMAR granted ATRX exclusive rights in the U.S., Canada and Europe to an oral low-dose interferon-alpha to treat Behcet's disease and oral papillomavirus warts in HIV-positive patients. AMAR will recei...